Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF Trial

Journal of the American College of Cardiology

Volumn 61, Issue 19, 2013, Pages 1998-2006

  Piccini, Jonathan P ^a   Stevens, Susanna R ^a   Lokhnygina, Yuliya ^a   Patel, Manesh R ^a   Halperin, Jonathan L ^b   Singer, Daniel E ^c   Hankey, Graeme J ^d   Hacke, Werner ^e   Becker, Richard C ^a   Nessel, Christopher C ^f   Mahaffey, Kenneth W ^a   Fox, Keith A A ^g   Califf, Robert M ^h   Breithardt, Günter ⁱ  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

atrial fibrillation; cardioversion; catheter ablation; rivaroxaban; stroke; warfarin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; RIVAROXABAN; WARFARIN;

ABLATION THERAPY; ADULT; AGED; ARTICLE; BRAIN EMBOLISM; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84877276344     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.025     Document Type: Article

References (17)

1. L.S. Wann, A.B. Curtis, K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 57 2011 1330 1337
2. M.M. Gallagher, B.J. Hennessy, N. Edvardsson Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion J Am Coll Cardiol 40 2002 926 933
3. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
4. M.R. Patel, K.W. Mahaffey, J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
5. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
6. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
7. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
8. D.W. Cockcroft, M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
9. K.A. Fox, J.P. Piccini, D. Wojdyla Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 2011 2387 2394
10. A.J. Camm, P. Kirchhof, G.Y.H. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
11. A. Wokhlu, K.H. Monahan, D.O. Hodge Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect J Am Coll Cardiol 55 2010 2308 2316
12. H. Oral, A. Chugh, M. Ozaydin Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation Circulation 114 2006 759 765
13. C.S. Elayi, M.G. Whitbeck, R. Charnigo Is there an association between external cardioversions and long-term mortality and morbidity? Insights from the atrial fibrillation follow-up investigation of rhythm management study Circ Arrhythm Electrophysiol 4 2011 465 469
14. G.Y. Lip, J. Zarifis, R.D. Watson, D.G. Beevers Physician variation in the management of patients with atrial fibrillation Heart 75 1996 200 205
15. A. Deshmukh, S. Pant, G. Kumar, Z. Bursac, H. Paydak, J.L. Mehta Comparison of outcomes of weekend versus weekday admissions for atrial fibrillation Am J Cardiol 110 2012 208 211
16. Healey JS, Oldgren J, Parekh A, et al. Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries: the RE-LY AF registry. Paper presented at the 2012 European Society of Cardiology Congress, August 29, 2012, Munich, Germany.
17. S. Themistoclakis, A. Corrado, F.E. Marchlinski The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation J Am Coll Cardiol 55 2010 735 743